Find My Journal

JK

Jean‐Jacques Kiladjian

Délégation Paris 5 FR

0000-0002-8121-438X

757

Publications

29,085

Citations

71

H-Index

272

i10-Index

4.57

2yr Mean Cite

-

Cite/Paper

Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar

Verify on Google Scholar

Publication & Citation Trends

Publications

0 total

Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Barbara Mora, F. Palandri, Paola Guglielmelli, Andrew T Kuykendall, M. Maffioli - Blood, 2026

Cited by 0 Semantic Scholar

Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement and Pemigatinib.

A. Vannucchi, Jay Patel, J. Kiladjian - Blood, 2026

Cited by 0 Semantic Scholar

Ruxolitinib treatment in patients with polycythemia vera reduces JAK2 variant allele frequency and improves symptom burden and hematocrit control

C. Harrison, J. Kiladjian, J. E. Hamer-Maansson, Ahmad Naim, F. Palandri - Therapeutic Advances in Hematology, 2026

Cited by 0 Semantic Scholar

Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement.

S. Verstovsek, J. Kiladjian, A. Vannucchi, Jay Patel, A. Rambaldi - NEJM Evidence, 2025

Cited by 2 Semantic Scholar

Response to the commentary by Xu et al. on the PV-AIM study

F. Heidel, M. Griesshammer, J. Kiladjian, Valerio Matthias Jens Eva Susanne Mike W. Kirsi Kenneth Ar De Stefano Zaiss Kisro Gückel Großer Zuurman Manz , Valerio De Stefano - Leukemia, 2025

Cited by 0 Semantic Scholar

Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera

Y. Beauverd, J. Ianotto, K. Thaw, M. Sobas, P. Sadjadian - Leukemia, 2025

Cited by 8 Semantic Scholar

Efficacy and safety of luspatercept (LUSPA) versus placebo (PBO) in patients (pts) with myelofibrosis (MF) on Janus kinase 2 inhibitor (JAKi) therapy who require red blood cell transfusions (RBCT): primary analysis of the Phase 3 randomized INDEPENDENCE trial

Francesco Passamonti, J. Kiladjian, J. Mascarenhas, C. Harrison, R. Mesa - Blood, 2025

Cited by 0 Semantic Scholar

JAK inhibitor selection in challenging scenarios of myelofibrosis: a review

P. Vachhani, R. Mesa, J. Mascarenhas, R. Rampal, Stephen T Oh - Haematologica, 2025

Cited by 3 Semantic Scholar

Outcome of patients with accelerated and blast‐phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination—A FIM study

C. Orvain, Suzanne Tavitian, Clémence Médiavilla, Françoise Boyer, A. Santagostino - HemaSphere, 2025

Cited by 1 Semantic Scholar

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

V. Gupta, J. Mascarenhas, H. Ali, David M. Ross, A. Yacoub - Blood, 2025

Cited by 0 Semantic Scholar

Research Topics

Myeloproliferative Neoplasms: Diagnosis and Treatment (620) Chronic Myeloid Leukemia Treatments (292) Acute Myeloid Leukemia Research (197) Eosinophilic Disorders and Syndromes (178) Kruppel-like factors research (135)

Affiliations

Délégation Paris 5

FR 2025 - 2025

University of Copenhagen

DK 2011 - 2011

Novartis (Switzerland)

CH 2011 - 2011

Centre National de la Recherche Scientifique

FR 2025 - 2025

Cleveland Clinic

US 2023 - 2023

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers